Show simple item record

dc.contributor.authorFonseca, Rafael
dc.contributor.authorBlood, Emily
dc.contributor.authorRué i Monné, Montserrat
dc.contributor.authorHarrington, David
dc.contributor.authorOken, Martin M.
dc.contributor.authorKyle, Robert A.
dc.contributor.authorDewald, Gordon W.
dc.contributor.authorVan Ness, Brian
dc.contributor.authorVan Wier, Scott A.
dc.contributor.authorHenderson, Kimberly J.
dc.contributor.authorBailey, Richard J.
dc.contributor.authorGreipp, Philip R.
dc.date.accessioned2016-05-18T07:49:03Z
dc.date.issued2003
dc.identifier.issn0006-4971
dc.identifier.urihttp://hdl.handle.net/10459.1/57039
dc.description.abstractNonrandom recurrent chromosomal abnormalities are ubiquitous in multiple myeloma (MM) and include, among others, translocations of the immunoglobulin heavy chain locus (IgH). IgH translocations in MM result in the up-regulation of oncogenes, and include more commonly t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23). Based on the recurrent nature of these translocations and their finding since the early stages of the plasma cell (PC) disorders, we hypothesized that they would confer biologic and clinical variability. In addition, deletions of 13q14 and 17p13 have also been associated with a shortened survival. We used cytoplasmic Ig–enhanced interphase fluorescent in situ hybridization to detect deletions (13q14 and 17p13.1), and translocations involving IgH in 351 patients treated with conventional chemotherapy entered into the Eastern Cooperative Oncology Group clinical trial E9486/9487. Translocations were frequently unbalanced with loss of one of the derivative chromosomes. The presence of t(4; 14)(p16;q32) (n 42; 26 vs 45 months, P < .001), t(14;16)(q32;q23) (n 15; 16 vs 41 months, P .003), 17p13 (n 37; 23 vs 44 months, P .005), and 13q14 (n 176; 35 vs 51 months, P .028) were associated with shorter survival. A strati- fication of patients into 3 distinct categories allowed for prognostication: poor prognosis group (t(4;14)(p16;q32), t(14; 16)(q32;q23), and 17p13), intermediate prognosis ( 13q14), and good prognosis group (all others), with median survivals of 24.7, 42.3, and 50.5 months, respectively (P < .001). This molecular cytogenetic classification identifies patients into poor, intermediate, and good risk categories. More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations.ca_ES
dc.language.isoengca_ES
dc.publisherAmerican Society of Hematologyca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1182/blood-2002-10-3017ca_ES
dc.relation.ispartofBlood, 2003, vol. 101, núm. 11, p. 4569-4575ca_ES
dc.rights(c) The American Society of Hematology, 2003ca_ES
dc.titleClinical and biologic implications of recurrent genomic aberrations in myelomaca_ES
dc.typearticleca_ES
dc.identifier.idgrec009171
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.identifier.doihttps://doi.org/10.1182/blood-2002-10-3017
dc.date.embargoEndDate10000-01-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record